Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup

The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD,…

• MJ
  Michael J. Fox Foundation for Parkinson's Research
• BA
  Bill and Melinda Gates Foundation
• NM
  National Multiple Sclerosis Society
• AA
  Alzheimer's Association
• EL
  Eli Lilly and Company
• R
  Roche
• B
  Biogen
• BF
  BrightFocus Foundation
• U
  UCB
• EJ
  EU Joint Programme – Neurodegenerative Disease Research
• GF
  GHR Foundation
• IP
  International Progressive MS Alliance
• EC
  European Commission

  Awards: 101034344, 831434, 860197
• Z
  ZonMw

  Award: 10510032120003
• NO
  Nederlandse Organisatie voor Wetenschappelijk Onderzoek
• E
  Eisai
• NN
  Novo Nordisk
• FE
  Fujirebio Europe
• AN
  Alzheimer Nederland
• NI
  National Institutes of Health

  Awards: U19AG078109, U19AG073153, R01AG062167, RF1AG052324, R01AG066203, U19AG024904, R01AG077507, R01AG070028, R01AG027161
• G
  Genentech
• GH
  GE Healthcare
• AR
  Avid Radiopharmaceuticals
• NI
  National Institute on Aging

  Awards: R01AG070028, U19AG073153, RF1AG052324, U19AG078109, R01AG066203, R01AG062167, U19AG024904, R01AG027161, R01AG077507